Skip directly to content

Welcome to the Pfizer Rare Diseases Consortium

Welcome to the Pfizer Rare Diseases Consortium, a ground-breaking interaction initially established between Pfizer and our founding collaborators the GMEC consortium of six major UK universities. The Pfizer RDC, which was established to accelerate the pace of innovation in delivering medicines for rare diseases, is now expanding beyond GMEC to engage with additional UK and European academic institutions.

News_Bottle
News_Hands
News_Girl

Our mission is to develop new medicines for the treatment of rare diseases by bringing academic scientists (from GMEC and other institutions) , physicians and patient groups together with Pfizer’s world class drug development expertise, tools and resources.

About_Hat
About_Man
About_Girl

We believe collaboration across the rare disease community is key to future drug development, and this belief sits at the heart of the RDC.

Team_Pill
Team_Syringe
Team_Chemistry

The RDC will accelerate the pace of innovation in delivering new rare disease medicines.

Current Call

Partners_Pill
Partners_Y
Partners_DNA

Our current call is for novel biologic strategies and molecules and AAV gene therapy programmes across the rare disease landscape.

 

We want to hear from scientists working in GMEC and RDC affiliated academic institutions who can apply through their university.

 

Click here if you would like to find out more about how your institution could become an RDC collaborator.